MedTrace Logo

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

NCT02386072 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1524

Last updated 2024-10-16

No results posted yet for this study

Summary

A study to identify factors that are associated with improved effectiveness in pharmacologic therapy of Overactive Bladder, from the patient perspective primarily measured by OAB-Q-SF (Overactive Bladder Questionnaire Short Form)

Conditions

  • Urinary Bladder Overactive
  • Overactive Bladder
  • Urinary Bladder Diseases
  • Urologic Diseases

Interventions

DRUG

mirabegron

oral

DRUG

antimuscarinic medication

oral

Sponsors & Collaborators

  • Astellas Scientific & Medical Affairs, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director Urology · Astellas Scientific & Medical Affairs, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-05
Primary Completion
2017-08-04
Completion
2017-08-04

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02386072 on ClinicalTrials.gov